Clinical trials: CHC
Chronic Hepatitis C
Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients
To compare the sustained virological response (SVR = ribonucleic acid (RNA) - hepatitis C virus (HCV) undetectable at week 24 before end the treatment) in chronic hepatitis C patients genotype 1-4 co-infected with HIV-HCV…
- Trial name
- PERICO (NCT00526448)
- Testing
- ribavirin, Peginterferon alfa-2a, epoetin beta
- Where
- 40 sites in Spain
- Volunteers
- 384 people
- Sponsor
- Hospital Carlos III, Madrid
Hepatitis C
The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC
The purpose of this study is to determine if administering Mogroside Sweetener "PureLo" (the study substance) for 14 days will lower the hepatitis C viral load and liver function alanine aminotransferase (ALT) levels.
- Trial name
- PureLo (NCT00926120)
- Testing
- Mogroside sweetener (PureLo)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brooke Army Medical Center
Chronic Hepatitis C
Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects
The purpose of this study is to determine if rosiglitazone, a medicine used to treat diabetes, improves response to anti-viral treatment.
- Trial name
- NCT00926016
- Testing
- Pioglitazone (Actos)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Brooke Army Medical Center
Hepatitis C, Chronic
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
This study will evaluate the addition of a higher-dose induction treatment period with peginterferon (PEG-IFN) alfa-2a (Pegasys) and ribavirin prior to standard-dose treatment with PEG-IFN alfa-2a and ribavirin, compared to…
- Trial name
- NCT00192647
- Testing
- PEG-IFN alfa-2a, Ribavirin
- Where
- 51 sites in Argentina, Australia and 4 more
- Volunteers
- 896 people
- Sponsor
- Hoffmann-La Roche
Mother-infant Relational Disturbances
Mother-Infant Psychoanalysis Project of Stockholm
Mother-infant relationship disturbances broadly comprise three areas; maternal distress, infant functional problems, and relationship difficulties.
- Trial name
- MIPPS (NCT00923559)
- Testing
- Treatment as Usual at Child Health Centre, Mother-Infant Psychoanalytic treatment (MIP)
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Karolinska Institutet
Chronic Hepatitis C
Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)
This is a multi-center, open-label clinical study. This study was aimed to assess the real-world effectiveness and safety of treatment with listed DAAs in patients with CHC and cirrhosis in Southern area of China.
- Trial name
- NCT03887637
- Testing
- DAAs
- Volunteers
- 180 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis C(CHC)
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.
- Trial name
- NCT01753570
- Testing
- MP-424, RBV(24 weeks), IFN beta(24 weeks)
- Where
- Japan
- Volunteers
- 74 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
This 2-arm study will compare the efficacy and safety of treatment with Pegasys (180 µg weekly) plus Copegus (800 mg daily) and Pegasys (180 µg weekly) plus Copegus (1000-1200 mg daily) in interferon-naive patients with CHC…
- Trial name
- NCT00353418
- Testing
- Peginterferon alfa-2a, Ribavirin
- Volunteers
- 415 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Comparison of Multiphase and Monophasic Arterial Hepatic MRI in the Detection of Arterial Enhancement of CHC Nodules
The detection and diagnosis of hepatocellular carcinoma is a public health issue. MRI is the most sensitive examination for diagnosis and especially hypervascularization in the arterial phase.
- Trial name
- CHIC MultiA (NCT04687280)
- Testing
- non interventional
- Volunteers
- 153 people
- Sponsor
- University Hospital, Angers
Liver Cirrhosis, Chronic Hepatitis C
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
This study evaluated the clinical response of the efficacy and safety of the combination therapy of peginterferon alfa-2a and ribavirin, compared with an antiviral treatment-free group in CHC patients with compensated LC.
- Trial name
- NCT00304551
- Testing
- peginterferon alfa-2a 180μg, peginterferon alfa-2a 90μg, ribavirin
- Where
- 8 sites in Japan
- Volunteers
- 180 people
- Sponsor
- Chugai Pharmaceutical
Hepatitis C, Hepatitis B
Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy
The literature suggests that there may be an association between hepatitis C and type 2 diabetes mellitus independent of the presence of cirrhosis, the likely mechanism for which is insulin resistance.
- Trial name
- NCT00188240
- Testing
- Pegasys; Copegus.
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Hepatitis C
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
The purpose of this study is to see which of two doses of PEG (polyethylene glycol) interferon alfa-2b in combination with Ribavirin for 48 weeks is more effective at elimination of hepatitis C.
- Trial name
- NCT00207363
- Testing
- Ribavirin, Peg interferon alfa 2b, induction therapy
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- Brooke Army Medical Center
Hepatitis C, Chronic
Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).
This study will examine the viral kinetics and pharmacokinetics of Pegasys plus ribavirin and PEG-Intron plus ribavirin in interferon-naive patients with CHC.
- Trial name
- NCT00087607
- Testing
- Ribavirin, Peginterferon alfa-2b (PEG-Intron), Peginterferon alfa-2a [Pegasys]
- Where
- 41 sites in United States
- Volunteers
- 385 people
- Sponsor
- Hoffmann-La Roche
Hepatocyte Receptor, Hepatocellular Carcinoma
Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients
Primary liver cancer or hepatocellular carcinoma (HCC) is the 7th most common cancer in humans; 9th in women (figures from the Association for Research against Cancer ARC).
- Trial name
- SLAMF3 (NCT03113604)
- Testing
- Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Chronic Hepatitis C
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
The purpose of this study is to evaluate the efficacy, safety and tolerability of Ravidasvir (ASC16) in combination with Ritonavir-boosted Danoprevir(ASC08) and Ribavirin in treatment-naive no-cirrhotic Taiwanese patients who…
- Trial name
- NCT03020095
- Testing
- Ravidasvir, Danoprevir, Ritonavir
- Volunteers
- 38 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Hepatitis C, Chronic
Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)
The objective is to evaluate the efficacy and safety of the combination therapy with subcutaneous (SC) Pegylated Interferon (PEG-IFN) alfa-2b 1.5 ug/kg/week plus low-dose ribavirin administered for 48 weeks in participants with…
- Trial name
- NCT00686777
- Testing
- Pegylated Interferon alfa-2b, Ribavirin
- Volunteers
- 75 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis…
- Trial name
- NCT03020004
- Testing
- Danoprevir, Ritonavir, peginterferon alfa-2a
- Volunteers
- 70 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Chronic Hepatitis C
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
A Phase 2 study to evaluate the safety and efficacy of two different once daily doses VX-135 in combination with ribavirin in treatment-naïve subjects with chronic hepatitis C
- Trial name
- NCT01726946
- Testing
- VX-135, ribavirin
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)
This open-label, non-comparative study will assess the safety and tolerability of individualized combination therapy with Copegus (ribavirin) and Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C.
- Trial name
- NCT01296971
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C
The purpose of this open-label study is to assess the safety, antiviral activity, and pharmacokinetics of 9 subcutaneous injections of miravirsen monotherapy (5 weekly doses over 5 weeks, followed by a further 4 doses once every…
- Trial name
- NCT01727934
- Testing
- Miravirsen sodium
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Santaris Pharma A/S